Surgical treatment of denture-induced fibrous hyperplasia with plasma rich in growth factors.
Denture-induced fibrous hyperplasia is a fibrous connective tissue lesion that commonly occurs in oral mucosa in patients showing important alveolar ridge atrophy. In this study, we propose Plasma Rich in Growth Factors (PRGF) to overcome constrains of traditional surgical treatment. Herein, we demonstrated that PRGF represents an autologous source of growth factors able to reduce the healing time of the alveolar mucosa and the discomfort of those patients. These properties are the result of PRGF's precise biological features that result in the following: reduction of duration and intensity of postsurgical pain, acceleration of re-epithelialization of the wound, and reduction of bleeding events and of edema. In conclusion, we showed that using PRGF on patients affected by denture-induced fibrous hyperplasia allows a short healing time, thereby reducing complications and overall improving their quality of life. The aims of this study were to evaluate the influence of PRGF-ENDORET on secondary re-epithelialization in vestibuloplasty after excision of denture irritation fibrous hyperplasia, with an explorative randomized case control trial with 10 patients, 5 patients treated with PRGF and 5 patients with traditional hemostasis, and to analyze differences with simple surgery, considering postoperative rapidity of re-epithelialization, comfort, and discomfort of patients, pain, swelling, and infections.
*SIOM Oral Surgery and Implantology Center, Turin, Italy †Department of Health Sciences "A. Avogadro," University of Eastern Piedmont, Novara, Italy ‡Trainer, Oral Surgery Unit, Dentistry Section §Consultant, Oral Surgery Unit, Dentistry Section, Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy.
Marco
M
Mozzati
Carmen
C
Mortellaro
Giorgia
G
Gallesio
Tiziana
T
Ruggiero
Renato
R
Pol
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000539:Alveolar Process / Q000187:drug effects* / Q000473:pathology*; D001688:Biological Products / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003824:Denture, Complete / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy / Q000473:pathology; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D062326:Re-Epithelialization / Q000187:drug effects; D014727:Vestibuloplasty
D001688:Biological Products; D036341:Intercellular Signaling Peptides and Proteins